The lucky break behind the first CRISPR treatment

December 7, 2023
The world’s first commercial gene-editing treatment is set to start changing the lives of people with sickle-cell disease. It’s called Casgevy, and it was approved last month in the UK. US approval is pending this week.  The treatment, which will be sold in the US by Vertex Pharmaceuticals, employs CRISPR, the Nobel-winning molecular scissors that have…

The Download: Google’s Gemini is here, and Sundar Pichai talks AI

December 7, 2023
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Google DeepMind’s new Gemini model looks amazing—but could signal peak AI hype Hype about Gemini, Google DeepMind’s long-rumored response to OpenAI’s GPT-4, has been building for months. Now, the company has finally revealed…

Top 3 Defense Stock Picks Illuminating the Market This Month

December 7, 2023
The escalating geopolitical upheaval has precipitated a surge in defense expenditure, positioning the defense industry to thrive. Therefore, fundamentally strong defense stocks General Dynamics Corporation (GD), Lockheed Martin (LMT), and…

EU ‘final’ talks to fix AI rules to run into second day — but deal on foundational models is on the table

December 7, 2023

As European Union lawmakers clock up 20+ hours of negotiating time in a marathon attempt to reach agreement on how to regulate artificial intelligence a preliminary accord on how to handle one sticky element — rules for foundational models/general purpose AIs (GPAIs) — has been agreed, according to a leaked proposal TechCrunch has reviewed. In […]

© 2023 TechCrunch. All rights reserved. For personal use only.